Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.
There are many topics related to the comprehension of hidradenitis suppurativa (HS) that require clinical investigation, including its hormone-related implications, variability, and impact on pediatric populations, said Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with the disease.
Transcript
What are the most critical research needs in HS?
I was just actually reading through an HS textbook and I was writing a list of things that we need to write articles on. I was also emailing a doctor that we've been working with about some study ideas and emailed him and was like: oh, here's another one that came up as a result of reading through this. So much of the areas of study and research that need to be done on HS have to do with—there’s so much unknown about this disease. I mean, even as far as how it's actually happening, what the sequence is, how it's happening, and why that's happening to us other than that it's an autoinflammatory condition, and our inflammation is just on overdrive.
There's so much research and studies to be done on this, it's incredible. There, I think, is a huge link—at least for most people in what we see in the patient population—it’s hormone related for a lot of people who get flares before their periods. There hasn't been a ton of research done on the hormonal link. A lot of the experience that patients have is different, even patient by patient, it doesn't affect us all the same way.
There's such a varied degree for every single potential thing with HS between people. So, it's really hard to gather super specific data on some of that, but there is so much of a need. So many things that you don't even think impact your HS. For me, I learned that mechanical stress was an issue when I was sitting at the office all day. I didn't even know that that was a thing until COVID-19 happened, and then I was working from home and didn’t have to be in the same seat all day and was like: oh, my flares have been dramatically decreased.
So, what can potentially be flares for HS I think is something that we need to look more into as well. There's so much—I really want to see more research in pediatrics. We work with PeDRA, Pediatric Dermatology Research Alliance, as well, and we’re trying to get more research done for pediatric HS, especially since that is such a huge issue for a lot of kids and it's misdiagnosed because people don't think that you can get HS until you start puberty. So much research to be done, and I'm excited that we're going to be able to be part of that.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More